Reviva Pharmaceuticals Hldg Inc (RVPH) Stock Price, Quote & News

Company Profile

Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attention-deficit/hyperactivity...

Industry: Biotechnology

Sector: Healthcare

Phone: 408 501 8881

Fax: 408 904 6270

Website: www.revivapharma.com

Address:

10080 N. Wolfe Road, Suite SW3-200, Cupertino, United States

Wampensau Apr. 13 at 6:15 PM

$RVPH Let’s goooo Only 91% down!!

0 · Reply

rocket_buddy Apr. 13 at 6:14 PM

$RVPH so

0 · Reply

RobbyAxelrod1 Apr. 13 at 6:09 PM

$RVPH This better be it.

0 · Reply

OatesTheGoat Apr. 13 at 6:06 PM

$RVPH .94 next EMA level (1 hour 200 EMA)

0 · Reply

MillennialTrades Apr. 13 at 5:59 PM

$RVPH bring these daily gains to $MAULCOIN.X and join the movement - you’re welcome

0 · Reply

OatesTheGoat Apr. 13 at 5:57 PM

$RVPH Testing this level now. Keep an eye

0 · Reply

papatrick Apr. 11 at 9:21 PM

$AVXL $IBRX $GLSI $RVPH so well said!! Missling is doing exactly that..taking his 800k$/year plus 500k options every 3-4 years and letting hedge funds short and play with SP...delaying everything, failing trials on purpose...but just slightly so shareholders see that the drug works and the potential but problems block approval and delay the whole process. That' exactly the modus of operation of Missling...

4 · Reply

RobbyAxelrod1 Apr. 11 at 9:05 PM

$RVPH I might be selling next week I gave it enough time to reach that 1$ .

0 · Reply

History101 Apr. 11 at 8:01 PM

$AVXL i am bullish on the science of AVXL and several other bios. however, i am not bullish on a lot of bio CEOs. with the exceptions of CEOs of $IBRX and $GLSI, and a few others, many bio CEOs either do not operate with a sense of urgency, or work for their hedge fund masters at the expense of retail. The problem is the CEO can gain by stringing out the trial periods (more time for big salaries and stock options to accumulate), and can lose lose by accelerating the timeline. At the expense of real life patients, who need these drugs. And it does not matter if the CEO is completely incompetent, like $RVPH. Frustrating.

1 · Reply

RobbyAxelrod1 Apr. 9 at 8:10 PM

$RVPH $$$

0 · Reply

Reviva Reports Full Year 2025 Financial Results and Recent Business Highlights

Mar 19, 2026, 12:49 PM EDT - 25 days ago

What's Behind The Drop In Reviva Pharmaceuticals Stock?

Mar 18, 2026, 10:34 PM EDT - 26 days ago

Reviva Pharmaceuticals Holdings, Inc. Announces Pricing of $10 Million Public Offering

Mar 18, 2026, 4:10 PM EDT - 26 days ago

Reviva Pharmaceuticals Holdings, Inc. Announces Proposed Public Offering

Dec 29, 2025, 8:00 AM EST - 3 months ago

Reviva to Present at the Sachs 9th Annual Neuroscience Innovation Forum

Dec 23, 2025, 9:26 AM EST - 3 months ago

FDA Asks Reviva Pharmaceuticals To Conduct Additional Phase 3 Study For Its Schizophrenia Drug

Dec 23, 2025, 8:00 AM EST - 3 months ago

Reviva Announces Regulatory Update Regarding the Development of Brilaroxazine for the Treatment of Schizophrenia

Nov 13, 2025, 4:05 PM EST - 5 months ago

Reviva Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Oct 28, 2025, 8:00 AM EDT - 5 months ago

Reviva to Present Negative Symptom Data for Brilaroxazine in Schizophrenia from the Phase 3 RECOVER Double-Blind and Open-Label Extension Trials at the CNS Summit 2025

Oct 7, 2025, 4:08 PM EDT - 6 months ago

Reviva to Participate in Key Opinion Leader Webinar Hosted by Alliance Global Partners

Sep 19, 2025, 7:01 AM EDT - 7 months ago

Top 3 Health Care Stocks That May Explode In September

ATYR BSX

Sep 18, 2025, 9:26 PM EDT - 7 months ago

Reviva Pharmaceuticals Holdings, Inc. Announces Pricing of $9 Million Public Offering

Aug 14, 2025, 4:25 PM EDT - 8 months ago

Reviva Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Jun 5, 2025, 8:00 AM EDT - 11 months ago

Reviva to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference

Jun 2, 2025, 7:00 AM EDT - 11 months ago

Reviva Announces Positive Full Dataset for 1-Year Phase 3 RECOVER Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia

May 15, 2025, 4:05 PM EDT - 11 months ago

Reviva Reports First Quarter 2025 Financial Results and Recent Business Highlights

Mar 30, 2025, 11:30 AM EDT - 1 year ago

Reviva to Present Brilaroxazine Topline Data for Long-Term OLE Portion of RECOVER Study in Schizophrenia at 2025 SIRS Congress

Feb 4, 2025, 8:00 AM EST - 1 year ago

Reviva to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Jan 30, 2025, 8:00 AM EST - 1 year ago

Reviva to Participate in the 2025 BIO CEO & Investor Conference

Jan 7, 2025, 8:00 AM EST - 1 year ago

Reviva to Participate in the Lytham Partners 2025 Investor Healthcare Summit

Dec 16, 2024, 5:18 PM EST - 1 year ago

Reviva Announces Proposed Public Offering

Nov 14, 2024, 5:25 PM EST - 1 year ago

Reviva Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Nov 6, 2024, 8:00 AM EST - 1 year ago

Reviva to Present Positive Speech Latency Data for Brilaroxazine in Schizophrenia From the Phase 3 RECOVER Trial at the CNS Summit 2024

Oct 31, 2024, 8:00 AM EDT - 1 year ago

Reviva to Participate in the UBS Global Healthcare Conference

Oct 8, 2024, 8:00 AM EDT - 1 year ago

Reviva to Participate in the 2024 Maxim Healthcare Virtual Summit

Oct 2, 2024, 8:30 AM EDT - 1 year ago

Reviva to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference

Aug 21, 2024, 6:00 AM EDT - 1 year ago

Reviva Pharmaceuticals Announces Pricing of $5.0 Million Underwritten Offering Priced At-the-Market Under Nasdaq Rules

Jul 9, 2024, 8:00 AM EDT - 1 year ago

Reviva Announces Grant of European Patent Covering Use of Brilaroxazine for the Treatment of Pulmonary Hypertension

May 29, 2024, 4:45 PM EDT - 2 years ago

Reviva Announces Closing of $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

May 28, 2024, 8:00 AM EDT - 2 years ago

Reviva Announces $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

May 21, 2024, 8:00 AM EDT - 2 years ago

Reviva to Participate in the BIO International Convention

May 15, 2024, 8:00 AM EDT - 2 years ago

Reviva Announces Enrollment Update for Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia

May 14, 2024, 8:00 AM EDT - 2 years ago

Reviva Reports First Quarter 2024 Financial Results and Recent Business Highlights

May 13, 2024, 8:00 AM EDT - 2 years ago

Reviva to Present New Preclinical Efficacy Data on Brilaroxazine in Idiopathic Pulmonary Fibrosis at 2024 ATS International Conference

May 9, 2024, 8:00 AM EDT - 2 years ago

Reviva to Present New Non-Clinical Pharmacology Data on Brilaroxazine at the ASPET 2024 Annual Meeting

Apr 15, 2024, 8:30 AM EDT - 2 years ago

Reviva Announces FDA Alignment on Brilaroxazine Clinical Trials for NDA in Schizophrenia

Apr 15, 2024, 8:05 AM EDT - 2 years ago

Reviva Reports Full Year 2023 Financial Results and Recent Business Highlights

Mar 28, 2024, 8:00 AM EDT - 2 years ago

Reviva to Present RECOVER Phase 3 Clinical Trial Data for Brilaroxazine in Schizophrenia at the SIRS 2024 Annual Meeting

Mar 26, 2024, 8:00 AM EDT - 2 years ago

Reviva to Present RECOVER Phase 3 Clinical Trial Data for Brilaroxazine in Schizophrenia at the ASCPT 2024 Annual Meeting

Mar 11, 2024, 8:00 AM EDT - 2 years ago

Reviva to Present at the UBS Virtual CNS Day

Mar 7, 2024, 8:00 AM EST - 2 years ago

Reviva to Present at the 36th Annual ROTH Conference

Feb 20, 2024, 8:00 AM EST - 2 years ago

Reviva Pharmaceuticals to Present at the 2024 BIO CEO & Investor Conference

Feb 6, 2024, 8:00 AM EST - 2 years ago

Reviva to Host KOL Event to Discuss Topline Data from Phase 3 RECOVER Trial of Brilaroxazine in Schizophrenia

Jan 25, 2024, 8:00 AM EST - 2 years ago

Reviva Pharmaceuticals to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference

Jan 10, 2024, 8:00 AM EST - 2 years ago

Reviva to Present at Webull LIVE! Healthcare Webinar on January 17

Jan 4, 2024, 8:00 AM EST - 2 years ago

Reviva Provides Corporate and Program Updates and Highlights Key Upcoming Milestones

Dec 11, 2023, 8:00 AM EST - 2 years ago

Reviva to Participate in the Zacks Small-Cap Research Life Sciences Investor Forum

Nov 30, 2023, 4:05 PM EST - 2 years ago

Reviva Pharmaceuticals to Participate in The Benchmark Company's Upcoming Discovery One-on-One Investor Conference

Wampensau Apr. 13 at 6:15 PM

$RVPH Let’s goooo Only 91% down!!

0 · Reply

rocket_buddy Apr. 13 at 6:14 PM

$RVPH so

0 · Reply

RobbyAxelrod1 Apr. 13 at 6:09 PM

$RVPH This better be it.

0 · Reply

OatesTheGoat Apr. 13 at 6:06 PM

$RVPH .94 next EMA level (1 hour 200 EMA)

0 · Reply

MillennialTrades Apr. 13 at 5:59 PM

$RVPH bring these daily gains to $MAULCOIN.X and join the movement - you’re welcome

0 · Reply

OatesTheGoat Apr. 13 at 5:57 PM

$RVPH Testing this level now. Keep an eye

0 · Reply

papatrick Apr. 11 at 9:21 PM

4 · Reply

RobbyAxelrod1 Apr. 11 at 9:05 PM

$RVPH I might be selling next week I gave it enough time to reach that 1$ .

0 · Reply

History101 Apr. 11 at 8:01 PM

1 · Reply

RobbyAxelrod1 Apr. 9 at 8:10 PM

$RVPH $$$

0 · Reply

BigBoyTroy Apr. 9 at 8:02 PM

$RVPH time stampbherevin stocktwits me and my discord was in early swinging. We green are you

0 · Reply

OatesTheGoat Apr. 9 at 6:44 PM

$RVPH Above the 4 hour 48 EMA this could see a nice move up

2 · Reply

RobbyAxelrod1 Apr. 9 at 6:10 PM

$RVPH This better be the move I'm looking for back to 1$.

0 · Reply

Shawns512 Apr. 9 at 5:11 PM

$RVPH

0 · Reply

Old_Bag Apr. 8 at 5:00 PM

$RVPH just checking in, any recent developments here or still dead money?

1 · Reply

RobbyAxelrod1 Apr. 8 at 12:46 PM

$RVPH Soon...

0 · Reply

RobbyAxelrod1 Apr. 7 at 10:27 PM

$RVPH Ok this is the move up since we're in 2nd quarter where the trial starts the MM are going to start moving this up in anticipation of 1st patient dosed pr.

0 · Reply

BigBoyTroy Apr. 7 at 8:52 PM

$FRGT $KPRX $MIGI $RVPH $ADTX My swing watchlist for tomorrow and the next 3 to 20 days or sooner ADTX FGRT KPRX MIGI always looking for dips before entering

1 · Reply

RobbyAxelrod1 Apr. 7 at 7:57 PM

$RVPH Go back to 1$ you pos!

0 · Reply

RobbyAxelrod1 Apr. 7 at 7:52 PM

$RVPH 👀

0 · Reply

RobbyAxelrod1 Apr. 7 at 6:42 PM

$RVPH Show me a sign and I'll buy a chunk.

0 · Reply

RobbyAxelrod1 Apr. 7 at 6:30 PM

$RVPH I 🤔 this is about to make another move.

0 · Reply

Market Cap	9.88M
Revenue (ttm)	0.00
Net Income (ttm)	-19.86M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	720,600
Avg Vol	583,829
Day's Range	N/A - N/A
Shares Out	12.81M
Stochastic %K	64%
Beta	0.64
Analysts	Strong Sell
Price Target	$12.67